乙肝感染的理想治愈方法：目标在望。
Ideal Cure for Hepatitis B Infection: The Target is in Sight.
作者信息
Anikhindi Shrihari A, Kumar Ashish, Sharma Praveen, Singla Vikas, Bansal Naresh, Arora Anil
机构信息
Department of Gastroenterology, Sir Ganga Ram Hospital, New Delhi, India.
Department of Pathology, Sir Ganga Ram Hospital, New Delhi, India.
出版信息
J Clin Exp Hepatol. 2018 Jun;8(2):188-194. doi: 10.1016/j.jceh.2017.10.002. Epub 2017 Nov 7.
Abstract
Hepatitis B virus (HBV) is one of the most common causes of liver cirrhosis and hepatocellular carcinoma. Despite recent strides in pharmacotherapy, complete cure of HBV infection still remains an enigma. The biggest obstacle in HBV therapy is clearance of covalently closed circular deoxyribonucleic acid (cccDNA). We discuss about the role of cccDNA in HBV life cycle, efficacy and shortcomings of currently available antivirals as well as promising novel targets to achieve ideal HBV cure.
摘要
乙型肝炎病毒（HBV）是肝硬化和肝细胞癌最常见的病因之一。尽管近期药物治疗取得了进展，但彻底治愈HBV感染仍是一个谜。HBV治疗的最大障碍是共价闭合环状脱氧核糖核酸（cccDNA）的清除。我们讨论了cccDNA在HBV生命周期中的作用、现有抗病毒药物的疗效和缺点，以及有望实现理想HBV治愈的新靶点。
相似文献
1
Ideal Cure for Hepatitis B Infection: The Target is in Sight.乙肝感染的理想治愈方法：目标在望。
J Clin Exp Hepatol. 2018 Jun;8(2):188-194. doi: 10.1016/j.jceh.2017.10.002. Epub 2017 Nov 7.
2
Current Status and Challenges in Anti-Hepatitis B Virus Agents Based on Inactivation/Inhibition or Elimination of Hepatitis B Virus Covalently Closed Circular DNA.基于乙型肝炎病毒共价闭合环状 DNA 的失活/抑制或清除的抗乙型肝炎病毒药物的现状与挑战。
Viruses. 2023 Nov 25;15(12):2315. doi: 10.3390/v15122315.
3
Hepatitis B Virus Core Protein Is Not Required for Covalently Closed Circular DNA Transcriptional Regulation.乙型肝炎病毒核心蛋白对于共价闭合环状 DNA 的转录调控并非必需。
J Virol. 2022 Nov 9;96(21):e0136222. doi: 10.1128/jvi.01362-22. Epub 2022 Oct 13.
4
Revisiting Hepatitis B Virus: Challenges of Curative Therapies.重新审视乙型肝炎病毒：治愈疗法的挑战。
J Virol. 2019 Sep 30;93(20). doi: 10.1128/JVI.01032-19. Print 2019 Oct 15.
5
Cellular DNA Topoisomerases Are Required for the Synthesis of Hepatitis B Virus Covalently Closed Circular DNA.细胞 DNA 拓扑异构酶是合成乙型肝炎病毒共价闭合环状 DNA 所必需的。
J Virol. 2019 May 15;93(11). doi: 10.1128/JVI.02230-18. Print 2019 Jun 1.
6
HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B.HBV cccDNA：病毒持续感染的储存库，也是慢性乙型肝炎治愈的关键障碍。
Gut. 2015 Dec;64(12):1972-84. doi: 10.1136/gutjnl-2015-309809. Epub 2015 Jun 5.
7
synthesis of hepatitis B virus nucleocapsids is dispensable for the maintenance and transcriptional regulation of cccDNA.乙肝病毒核衣壳的合成对于共价闭合环状DNA（cccDNA）的维持和转录调控并非必需。
JHEP Rep. 2020 Oct 14;3(1):100195. doi: 10.1016/j.jhepr.2020.100195. eCollection 2021 Feb.
8
Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients.血清乙型肝炎核心相关抗原 (HBcrAg) 与慢性乙型肝炎患者共价闭合环状 DNA 转录活性相关。
J Hepatol. 2019 Apr;70(4):615-625. doi: 10.1016/j.jhep.2018.11.030. Epub 2018 Dec 7.
9
Nonproductive Hepatitis B Virus Covalently Closed Circular DNA Generates HBx-Related Transcripts from the HBx/Enhancer I Region and Acquires Reactivation by Superinfection in Single Cells.非生产性乙型肝炎病毒共价闭合环状 DNA 从 HBx/增强子 I 区产生与 HBx 相关的转录本，并通过单细胞中的再感染获得重新激活。
J Virol. 2023 Jan 31;97(1):e0171722. doi: 10.1128/jvi.01717-22. Epub 2022 Dec 7.
10
Forkhead O Transcription Factor 4 Restricts HBV Covalently Closed Circular DNA Transcription and HBV Replication through Genetic Downregulation of Hepatocyte Nuclear Factor 4 Alpha and Epigenetic Suppression of Covalently Closed Circular DNA via Interacting with Promyelocytic Leukemia Protein.叉头框转录因子 4 通过与早幼粒细胞白血病蛋白相互作用，抑制肝细胞核因子 4α 的遗传下调和共价闭合环状 DNA 的表观遗传抑制，从而限制 HBV 共价闭合环状 DNA 的转录和 HBV 复制。
J Virol. 2022 Jul 13;96(13):e0054622. doi: 10.1128/jvi.00546-22. Epub 2022 Jun 13.
引用本文的文献
1
Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection.新型衣壳组装调节剂 JNJ-64530440 单药治疗初治慢性乙型肝炎病毒感染患者 4 周的安全性、抗病毒活性和药代动力学。
J Antimicrob Chemother. 2022 Mar 31;77(4):1102-1110. doi: 10.1093/jac/dkab491.
2
Immunological Analysis of the Hepatitis B Virus "a" Determinant Displayed on Chimeric Virus-Like Particles of Nodavirus Capsid Protein Produced in 9 Cells.对在9细胞中产生的诺达病毒衣壳蛋白嵌合病毒样颗粒上展示的乙型肝炎病毒“a”决定簇的免疫学分析。
Vaccines (Basel). 2020 Jun 4;8(2):275. doi: 10.3390/vaccines8020275.
3
Mapping the Interactions of HBV cccDNA with Host Factors.HBV cccDNA 与宿主因子相互作用的研究。
Int J Mol Sci. 2019 Sep 1;20(17):4276. doi: 10.3390/ijms20174276.
本文引用的文献
1
Toward Elimination of Hepatitis B Virus Using Novel Drugs, Approaches, and Combined Modalities.利用新型药物、方法和联合模式实现乙型肝炎病毒的消除
Clin Liver Dis. 2016 Nov;20(4):737-749. doi: 10.1016/j.cld.2016.07.001. Epub 2016 Aug 30.
2
The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013.1990年至2013年病毒性肝炎的全球负担：全球疾病负担研究2013的结果。
Lancet. 2016 Sep 10;388(10049):1081-1088. doi: 10.1016/S0140-6736(16)30579-7. Epub 2016 Jul 7.
3
Kinetics of serum HBsAg and intrahepatic cccDNA during pegylated interferon therapy in patients with HBeAg-positive and HBeAg-negative chronic hepatitis B.聚乙二醇干扰素治疗 HBeAg 阳性和 HBeAg 阴性慢性乙型肝炎患者血清 HBsAg 和肝内 cccDNA 的动力学。
J Med Virol. 2017 Jan;89(1):130-138. doi: 10.1002/jmv.24601. Epub 2016 Jun 21.
4
Review article: novel therapies for hepatitis B virus cure - advances and perspectives.综述文章：乙肝病毒治愈的新型疗法——进展与展望
Aliment Pharmacol Ther. 2016 Aug;44(3):213-22. doi: 10.1111/apt.13694. Epub 2016 Jun 15.
5
Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B.慢性乙型肝炎患者对抗核苷类似物抗病毒反应的停药后持久效应
BMC Gastroenterol. 2016 Mar 17;16:38. doi: 10.1186/s12876-016-0454-z.
6
New therapeutic agents for chronic hepatitis B.慢性乙型肝炎的新型治疗药物。
Lancet Infect Dis. 2016 Feb;16(2):e10-21. doi: 10.1016/S1473-3099(15)00436-3. Epub 2016 Jan 13.
7
Molecular Determinants of GS-9620-Dependent TLR7 Activation.GS-9620 依赖性 TLR7 激活的分子决定因素
PLoS One. 2016 Jan 19;11(1):e0146835. doi: 10.1371/journal.pone.0146835. eCollection 2016.
8
Recent developments in antivirals against hepatitis B virus.乙型肝炎病毒抗病毒药物的最新进展。
Virus Res. 2016 Feb 2;213:205-213. doi: 10.1016/j.virusres.2015.12.014. Epub 2015 Dec 28.
9
Hepatitis B virus therapy: What's the future holding for us?乙肝病毒治疗：我们的未来会怎样？
World J Gastroenterol. 2015 Nov 28;21(44):12558-75. doi: 10.3748/wjg.v21.i44.12558.
10
Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013.全球慢性乙型肝炎病毒感染患病率的估计：1965 年至 2013 年发表数据的系统评价。
Lancet. 2015 Oct 17;386(10003):1546-55. doi: 10.1016/S0140-6736(15)61412-X. Epub 2015 Jul 28.
Zotero 插件